947669-91-2
947669-91-2 性质
储存条件 | Store at +4°C |
---|---|
溶解度 | DMSO : 17.33 mg/mL (39.61 mM; 需要超声波)H2O : < 0.1 mg/mL (不溶) |
形态 | 粉末 |
颜色 | 白色至米白色 |
947669-91-2 用途与合成方法
IC50: 70 nM (ABHD6)
At 1 h after WWL70 (10 μM) treatment, 2-Arachidonoylglycerol (2-AG) is increased by 20% compare to untreated cells. At either 1 or 10 μM, WWL70 completely blocks the lipopolysaccharide (LPS)-induced increase of PGE 2 . The enhanced mRNA expression of mPGES-1 and mPGES-2 by LPS is also reduced by WWL70. The IC 50 of WWL70 to inhibit the PGE 2 biosynthesis is about 100 nM.
Although post-treatment with WWL70 at 5 mg/kg does not have any effect, treatment with WWL70 at 10 mg/kg improves the performance significantly. WWL70 treatment improves motor coordination of traumatic brain injury (TBI) mice in a concentration dependent manner. The latency to fall in animals treated with WWL70 at 5 mg/kg increases from 74.92±4.8 to 99.57±5.21 on day 3 (p<0.01) and from 87.32±4.42 to 100.14±3.56 on day 7 (p<0.05) post-injury when compare with the vehicle-TBI groups. At 10 mg/kg, WWL70 treatment improves motor coordination starting on day 1 post-injury. WWL70 treatment completely restores the ability of TBI mice to continuously alternate arms during Y maze exploration (69.67±4.98 %).
947669-91-2 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-100337 | 1 mg | 450 | ||
2024-11-08 | HY-100337 | 947669-91-2 | 947669-91-2 | 5mg | 990 |